Our results highlighted the efficacy of anti-HIF-1α siRNA2-loaded NPs for gene knockdown both in vitro and in vivo, proving their potential in tumor targeting and for their use in combination therapy with anti-tumoral drugs and/or radiotherapy. This evidence concerns the gene HIF1A and neoplasm.